On June 23, 2023 Nexi, reported that its ‘first-in-class’ drug with its platform technology and antibodies to discover factors that cause refractoriness to existing cancer immunotherapy drugs, is accelerating with the goal of submitting a clinical trial plan (IND) in the first half of next year (Press release, NEX-I, JUN 23, 2023, View Source;mode=VIEW&num=44&category=&findType=&findWord=&sort1=&sort2=&page=1 [SID1234643438]). The company is preparing to emerge as a dark horse in the domestic bio industry with a two-track strategy that also looks at the possibility of technology transfer, including collaboration with global pharmaceutical companies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Kyung-wan Yoon, CEO of NEXI, said, "During the last BioUSA period, we continued discussions with a number of global pharmaceutical companies focusing on preclinical data of cancer immunotherapy drugs currently under development. As the preclinical data is positive and we are targeting a completely new target with First in Class. "I’m looking forward to the next process," he said.
NexI is developing innovative new drugs that can treat incurable cancers that do not respond to immunotherapy. We developed a platform to identify the mechanisms that cause refractoriness to anti-cancer immunotherapy and discover the causative factors of refractoriness. In addition, innovative immunotherapy drugs ‘NXI-101’ and ‘NXI- 201’ is being developed.
Non-small cell lung cancer was given priority and more than 20 types of immunotherapy-refractory cancer models, including colon cancer and cervical cancer, were constructed.
Nexi was founded in 2021 by CEO Yoon, who served as Genome & Company’s vice president (CSO). Although it is a new company, it has a large number of professional researchers who have been studying cancer immunotherapy and refractoriness for more than 20 years, and is attracting attention from the industry by producing remarkable results one after another in a short period of time. Daewoong Pharmaceutical participated in the Pre-A Series investment, and Green Cross later participated in the Series A investment, attracting an investment worth 22 billion won last year, a cold period for bio investment.
CEO Yoon said, "We are developing our core pipeline, NXI-101, with the goal of applying for IND and administering the first patient in April next year," and added, "We will increase the likelihood of success in technology commercialization in the global market."